Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for… Read More..

Strategic expansion into essential healthcare sector demonstrates NextNRG'senergy-agnostic technology and own-and-operate model Projects establish NextNRG as dedicated energy provider under long-term contracts to facilities requiring mandatory continuous power MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI driven energy innovation transforming how energy is… Read More..

AI-Driven Energy Pioneer Delivers Sixth Consecutive Record Month Company on Clear Path to $100 Million Revenue Run-Rate with Canadian Acquisition MIAMI, July 10, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (Nasdaq: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered through its Next Utility Operating… Read More..